Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of uric acid with febuxostat it is hypothesized that the levels of oxidative stress in adipose tissue (obtained by fat biopsy) will decrease.

Primary aims of the study are to determine whether febuxostat therapy in overweight or obese, diabetic patients with stage 3 Chronic Kidney Disease (CKD) and high serum uric acid levels

1. will affect adipose tissue concentrations of thiobarbituric acid reactive substance (TBARS), a marker of oxidative stress

2. will affect adipose tissue expression and concentrations of adiponectin; and

3. will affect urinary concentrations of transforming growth factor (TGF)- B1.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Collaborator: Takeda
• Treatments: Febuxostat

Criteria

Inclusion Criteria:

• Age > 18 years

• BMI > 25 kg/m2

• type 2 diabetes

• serum uric acid ≥ 5.5 mg/dl in men and ≥ 4.6 mg/dl in women

• eGFR 30-60 mL/min/1.73m2

Exclusion Criteria:

• History of gout

• concurrent use of azathioprine, mercaptopurine, theophylline, allopurinol, thiazolidinediones or warfarin

• concurrent use of metformin

• current antibiotic therapy

• pregnant women

• prisoners